Skip to content

Assessment of Post-traumatic Stress Disorder (PTSD) in Patients Monitored for Cytomegalovirus (CMV) Seroconversion During Pregnancy,

Assessment of Post-traumatic Stress Disorder (PTSD) in Patients Monitored for Cytomegalovirus (CMV) Seroconversion During Pregnancy, Without Ultrasound Signs or With Non-serious Ultrasound Signs of Maternal-fetal CMV Infection.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04658810
Acronym
PTSD CMV
Enrollment
87
Registered
2020-12-08
Start date
2021-05-02
Completion date
2021-08-02
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus Infections, Mothers, Pregnancy Related

Keywords

CMV, Pregnancy, PTSD

Brief summary

Reports of maternal seroconversion to CMV during pregnancy can be extremely stressful. This virus is little known to the general public and searching for information on the Internet quickly leads to a consultation of a site mentioning the risk of severe psychomotor retardation in the event of prenatal cytomegalovirus infection. The psychological repercussions in the event of prenatal CMV infection with criteria of severity, leading or not to a request for IMG, is undeniable, but no study has investigated the consequences of seroconversion to CMV without transmission of the virus to the patient fetus, or in the case of transmission without criteria of seriousness, on the patient's experience during and after her pregnancy. Such a study would, if necessary, improve the care and support of these future mothers

Interventions

OTHERAssessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)

Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults * Referred to the 3 DAN centers with maternal seroconversion to CMV during their pregnancy, confirmed, with or without confirmed prenatal transmission. * Presence of ultrasound signs without criteria of seriousness if the materno-fetal infection is proven. * Support between January 1, 2008 and December 31, 2020. * No opposition from patient

Exclusion criteria

* Reversed or anteconceptional CMV seroconversion * Concomitant infection with another infectious agent and suspected cross-reaction * Multiple pregnancy * Ultrasound and / or MRI severity criteria * Medical termination of pregnancy * Fetal death in utero * Birth \<32 weeks and / or birth weight \<1500 grams (birth criteria in maternity level IIA) * Intercurrent event that may be the cause of an abnormality in psychomotor development * Patients protected by justice

Design outcomes

Primary

MeasureTime frameDescription
PTSD evaluationThrough study completion, 3 monthsAssessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder scale (PPQ questionnaire)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026